Clinical trials: Microscopic Colitis, active
Microscopic Colitis
A Study to Investigate the Efficacy and Safety of SAR444336 in Adults With Microscopic Colitis in Clinical Remission
This is a parallel, placebo-controlled, multicenter, randomized, double-blind, Phase 2, proof of concept study. The study aims to evaluate the efficacy and safety of SAR444336 in adult participants with microscopic colitis.
- Trial name
- NCT07156175
- Testing
- SAR444336
- Where
- 24 sites in Belgium, Denmark and 7 more
- Volunteers
- 54 people
- Sponsor
- Sanofi
Inflammatory Bowel Disease (IBD), Irritable Bowel Syndrome (IBS)
Enabling Microbiomics- Driven Personalized Nutrition
The goal of this observational research study is to determine how diet contributes to various gastrointestinal related conditions.
- Conditions
- Inflammatory Bowel Disease (IBD), Irritable Bowel Syndrome (IBS), Celiac Disease, Diarrhea
- Trial name
- EMPOWER (NCT06657001)
- Where
- United States
- Volunteers
- 4,001 people
- Sponsor
- Mayo Clinic
Microscopic Colitis
Efficacy and Safety of Budesonide MMX® vs. Budesonide CR for Induction of Remission in Microscopic Colitis
The purpose of this research study is to compare how well two formulations of budesonide (budesonide MMX [Cortiment] and budesonide CR [Entocort]) work for treating patients with microscopic colitis.
- Trial name
- NCT05915104
- Testing
- Budesonide MMX®, Budesonide controlled ileal release (CR) capsules
- Where
- Canada
- Volunteers
- 80 people
- Sponsor
- University of Calgary
Microscopic Colitis
Efficacy and Safety of Oral Rifaximin in Patients With Active Microscopic Colitis
This is an open label study looking at rifaximin therapy for the treatment of microscopic (collagenous or lymphocytic) colitis.
- Trial name
- NCT04043897
- Testing
- Rifaximin 550mg
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Eugene F Yen, MD